Company news
Mind Cure Health Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM's AI-Driven Psychedelic Digital Therapeutic Technology
March 19, 2021
MINDCURE Names Tarik Lebbadi as Chief Operating Officer
March 15, 2021
MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
March 9, 2021
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
March 4, 2021
MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
March 3, 2021
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
March 2, 2021
Mind Cure Announces Addition of Global Technology Leader Robert C. Hill to Board of Directors
February 22, 2021
MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform
February 18, 2021
Mind Cure Comments on Recent Promotional Activity
February 17, 2021
Mind Cure Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics
February 17, 2021
MINDCURE's Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product Discovery and Lead Optimization
February 16, 2021
MINDCURE Announces Listing of Warrants
February 11, 2021
Mind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
February 10, 2021
MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Category
January 26, 2021
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
January 22, 2021
Mind Cure Health Inc. Announces an Increase to Previously Announced Bought Deal Public Offering
January 22, 2021
Mind Cure Health Inc. Announces $10 Million Bought Deal Public Offering
January 21, 2021
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
January 21, 2021
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
January 12, 2021
Mind Cure Announces Build-Out of Digital Therapeutics, iSTRYM: A Technology Platform for Mental Wellness Optimization & Psychedelic Research
January 6, 2021
Mind Cure Announces Retail Roll Out of Nootropics Lineup Across North America with Body Energy Club
December 31, 2020
Mind Cure Announces Novel Supplement Product to Address Teen Wellness
December 29, 2020
Mind Cure Moves into Psychedelic Assisted Therapy with British Columbia Location Offering Ketamine and Psilocybin Therapy
December 10, 2020
Mind Cure Health Inc. Announces Participation in the Benzinga Global Small Cap Conference
December 9, 2020
Mind Cure Announces its Research Program with Psychedelic Compounds
December 8, 2020
Mind Cure Announces Eligibility for DTC Trading
December 2, 2020
Mind Cure Promotes Kelsey Ramsden to President and Chief Executive Officer
December 1, 2020
Mind Cure Announces Closing of Oversubscribed $3.6 Million Offering
November 19, 2020
Mind Cure Announces Non-Brokered Private Placement of $3 Million
November 13, 2020
Mind Cure Announces Hiring of Award-Winning Experimental Scientist Dr. Ryan Hartwell as Chief Science Officer
November 10, 2020
Mind Cure Announces LOI for Acquisition of Epiphany360 Digital Therapeutics Platform for Treating Mental Health
October 21, 2020
Mind Cure Announces Geoff Belair as Chief Technology Officer
October 15, 2020
Mind Cure Announces Addition of Neuroscientist Dr. Wolfram Tetzlaff to Scientific Advisory Board
October 13, 2020
Health and Wellness Industry Tastemaker Jon Bier Joins Mind Cure's Advisory Board
October 8, 2020
Mind Cure Welcomes Dr. Jason Wallach to Scientific Advisory Board
October 7, 2020
Mind Cure Welcomes Award-Winning Journalist and Science Researcher Hamilton Morris to Advisory Board
October 6, 2020
Dr. Dan Engle Joins Mind Cure's Advisory Board
October 1, 2020
Mind Cure Announces Kelsey Ramsden as new Chief Operating Officer
September 29, 2020
Mind Cure adds Alain Roy as a product development specialist
September 24, 2020
Mind Cure Receives Health Canada Authorization to Sell its Moonbeam Mushroom Products in Canada
September 23, 2020
Mind Cure announces commencement of trading on the CSE
September 21, 2020
Mind Cure Announces Closing of Oversubscribed Upsized Initial Public Offering
September 17, 2020
CSE Bulletin: Appointment of Market Maker - Mind Cure Health Inc. (MCUR)
September 16, 2020